Literature DB >> 2874367

Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes.

S P O'Rahilly, Z Nugent, A S Rudenski, J P Hosker, M A Burnett, P Darling, R C Turner.   

Abstract

Continuous infusion of glucose with model assessment was used to measure glucose tolerance, beta-cell function, and insulin sensitivity in 154 first-degree relatives of 55 patients with type-2 diabetes. The plasma glucose achieved at 1 h was normally distributed in normal control subjects, but 31 (20%) of relatives of type-2 diabetics had values above the normal distribution mean +2 SD. Insulin secretion, assessed from the first or second phase plasma-C-peptide responses, was significantly lower in the glucose-intolerant relatives than in normoglycaemic relatives of similar sex, age, and obesity. beta-cell function, estimated by means of model analysis, was severely impaired in the glucose-intolerant relatives but was not impaired in the normoglycaemic relatives (geometric mean 41% and 109% of normal beta-cell response, respectively). Reduced beta-cell function was found with all degrees of glucose intolerance, whereas only the more severely hyperglycaemic relatives had impaired insulin sensitivity. This suggests that the primary defect in familial type-2 diabetes is beta-cell dysfunction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874367     DOI: 10.1016/s0140-6736(86)90052-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

1.  Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects.

Authors:  L Mykkänen; S M Haffner; J Kuusisto; K Pyörälä; C N Hales; M Laakso
Journal:  Diabetologia       Date:  1995-10       Impact factor: 10.122

Review 2.  The chronic cardiovascular risk factor syndrome (syndrome X): mechanisms and implications for atherogenesis.

Authors:  S C Bain; P M Dodson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 3.  Insulin resistance in non-insulin-dependent diabetes mellitus. A review.

Authors:  A A Alzaid
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

4.  The association of the insulin resistance syndrome with impaired glucose tolerance and NIDDM in the Japanese general population: the Hisayama study.

Authors:  T Ohmura; K Ueda; Y Kiyohara; I Kato; H Iwamoto; K Nakayama; K Nomiyama; S Ohmori; T Yoshitake; A Shinkawa
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

5.  Insulin resistance in relatives of NIDDM patients: the role of physical fitness and muscle metabolism.

Authors:  B Nyholm; A Mengel; S Nielsen; C Skjaerbaek; N Møller; K G Alberti; O Schmitz
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

Review 6.  Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

Authors:  L C Groop; E Widén; E Ferrannini
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

7.  Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.

Authors:  M Farrer; F L Game; C J Albers; H A Neil; P H Winocour; M F Laker; P C Adams; K G Alberti
Journal:  BMJ       Date:  1993-10-02

8.  Clinical Characteristics of Type 2 Diabetes Patients according to Family History of Diabetes.

Authors:  Seung Uk Jeong; Dong Gu Kang; Dae Ho Lee; Kang Woo Lee; Dong-Mee Lim; Byung Joon Kim; Keun-Yong Park; Hyoun-Jung Chin; Gwanpyo Koh
Journal:  Korean Diabetes J       Date:  2010-08-31

Review 9.  Plasma glucose concentration and prediction of future risk of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 10.  Slow and steady is the key to beta-cell replication.

Authors:  Kristen Brennand; Doug Melton
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.